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• We included 1746 acute IS/TIA consecutive patient 
admissions (years 2009-2018) with a readable 
T2*gradient-echo MRI sequence (541 excluded) and IDU 
data (255 excluded).
• CMB rating followed standardized guidelines and CMB 
were grouped topographically into lobar, deep or 
infratentorial.
• Univariate analysis was used to assess vascular risk 
factors by IDU and CMB status.
• Multivariable logistic/Poisson regression was used to 
assess the association between IDU and CMB 
presence/number.
• Interaction analysis was used to study the relation between 
drug subtype and CMB presence/number.
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Introduction Results 
• Cerebral microbleeds (CMB) are small hypointensities on 
MRI that are representative of cerebral small vessel 
disease (CSVD) and are associated with stroke incidence, 
recurrence and complications.
• Illicit drug use (IDU) also has been associated with CSVD, 
but the relationship between IDU and CMB has been 
poorly elucidated.
• We conducted a retrospective study in post-ischemic 
stroke (IS)/transient ischemic accident (TIA) patients to 
delineate this relationship.
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• We found in our predominately minority, acute IS/TIA 
population that:
• Patients with IDU were younger, had lower prevalence of                
traditional risk factors but were more likely smokers.
• Those with IDU and CMB were older, had lower BMIs, and 
were more likely to have CKD or previous IS/TIA than those 
without CMB.
• Cocaine and opiate use were associated with higher CMB 
number.
• Those with opiate use had a preponderance of deep CMB
• Given the ongoing drug abuse epidemic, further studies are 
needed to fully characterize the impact of IDU on CSVD 
measures, including CMB, and clinical consequences.
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Table 1: Univariate Analysis: Patient Characteristic by Illicit Drug Use
Characteristics No IDU Group (N= 1505) Yes IDU Group (N= 241) P-Value
Age, Mean±SD 66.2±13.7 54.6±10.9 <0.001*
Male, N (%) 757 (50.3) 171 (71) <0.001*
HTN 1355 (90) 199 (82.6) 0.001*
DM 747 (49.6) 98 (40.7) 0.01*
DLP 677 (45) 93 (38.6) 0.063
CAD 232 (15.4) 30 (12.4) 0.231
CKD 93 (6.2) 12 (5) 0.467
BMI, Mean±SD 28.2±6 27.6±5.5 0.171
Previous CVA, N (%) 439 (29.2) 73 (30.3) 0.723
Never Smoker 753 (51.5) 24 (10)
<0.001*Former Smoker 495 (33.8) 67 (28)
Current Smoker 215 (14.7) 148 (61.9)
White 391 (26) 44 (18.4)
<0.001*Black 803 (53.5) 162 (67.8)
ORG 307 (20.5) 33 (13.8)
Table 2: Univariate Analysis: Patient Characteristics by CMB and Illicit Drug Use (IDU) Status
Characteristics
No IDU, No CMB 
(N=1004)
No IDU, Yes CMB 
(N=501)
P-Value
IDU Yes, CMB No 
(N=167)
IDU Yes, CMB Yes 
(N=74)
P-Value
Age, Mean±SD 65.4±13.8 67.9±13.3 0.001* 53.6±10.5 56.9±11.5 0.036*
Male, N (%) 519 (51.7) 238 (47.5) 0.126 113 (67.7) 58 (78.4) 0.091
HTN 887 (88.3) 468 (93.4) 0.002* 134 (80.2) 65 (87.8) 0.151
DM 510 (50.8) 237 (47.3) 0.202 68 (40.7) 30 (40.5) 0.979
DLP 450 (44.8) 227 (45.3) 0.857 65 (38.9) 28 (37.8) 0.873
CAD 157 (15.6) 75 (15) 0.735 22 (13.2) 8 (10.8) 0.608
CKD 58 (5.8) 35 (7) 0.359 5 (3) 7 (9.5) 0.033*
BMI, Mean±SD 28.2±5.8 28.2±6.3 0.812 28.1±5.9 26.6±4.4 0.039*
Previous CVA, N (%) 282 (28.1) 157 (31.3) 0.191 42 (25.1) 31 (41.9) 0.009*
Never Smoker 486 (49.3) 267 (55.9) 0.005* 13 (7.9) 11 (14.9) 0.058
Former Smoker 335 (34) 160 (33.5) 0.005* 42 (25.5) 25 (33.8) 0.058
Current Smoker 164 (16.6) 51 (10.7) 0.005* 110 (66.7) 38 (51.4) 0.058
White 273 (27.3) 118 (23.6) 0.132 33 (20) 11 (14.9) 0.505
Black 517 (51.7) 286 (57.1) 0.132 108 (65.5) 54 (73) 0.505
ORG 210 (21) 97 (19.4) 0.132 24 (14.5) 9 (12.2) 0.505
Abbreviations: IDU, illicit drug use; SD, standard deviation; HTN, hypertension; DM, diabetes mellitus; DLP, dyslipidemia; CAD, coronary artery disease; CKD, chronic kidney disease; 
BMI, body mass index; CVA, cerebrovascular accident; ORG, other racial group; N, number of patient records in each group. Previous CVA includes previous ischemic stroke and 
transient ischemic accident. T-test was used for univariate analysis of continuous variables, while Pearson’s chi-squared was used for categorical data. * Indicates a p-value less than 
0.05.
Abbreviations: SD, standard deviation; HTN, hypertension; DM, diabetes mellitus; DLP, dyslipidemia; CAD, coronary artery 
disease; CKD, chronic kidney disease; BMI, body mass index; CVA, cerebrovascular accident; ORG, other racial group; N, 
number of patient records in each group. Previous CVA includes previous ischemic stroke and transient ischemic accident. T-
test was used for univariate analysis of continuous variables, while Pearson’s chi-squared was used for categorical data. * 
Indicates a p-value less than 0.05.
• Of those with a history of IDU, 4.6% (n=11) had a history of amphetamine usage, 65.1% 
(n=157) had a history of cocaine usage, 24.5% (n=59) had a history of opiate/heroin usage, 
and 44.8% (n=108) had a history of cannabis usage
• CMB were observed in 32.9% (n=575) of our patients. The median number of CMB in 
patients with CMBs was 2. 
• CMB topographic location was 53.8% lobar, 27.3% deep, and 18.8% infratentorial.
• When controlled for hypertension, previous CVA, age, and sex, Poisson and logistic 
regression revealed no association between any IDU and CMB number or presence, 
respectively. 
• However, we observed a significant interaction by drug type: in patients that used either 
cocaine or opiates, there was a significant association with CMB burden (p<0.001 for both).
Abbreviations: CMB, cerebral microbleed; IDU, illicit drug use; N, number of 
patient records in each group. Cocaine included reported history or urine 
toxicology of cocaine or crack. Opiates included reported history of opiate, 
heroin, buprenorphine, methadone, codeine, or fentanyl abuse, or urine 
toxicology of the above excluding opiates. Pearson’s chi-squared was used 
to compare differences in topographical distribution of CMB. * Indicates a 
p-value less than 0.05.
Table 4: Multivariable Analysis: Drug Effects on CMB Number
Drug Category Controlled Contrasts, 95% CI P-Value
Cocaine 0.24 (0.09,0.38) 0.001*
Opiates 0.31 (0.08,0.52) 0.006*
Abbreviations: CMB, cerebral microbleed; CI, confidence interval; N, number of patient records in each group. 
Contrasts represent the average number of extra CMB with use of the specific drug compared to no use of the specific 
drug. Controlled contrast models included age, sex, hypertension diagnosis, and history of previous CVA in a Poisson 
model. Cocaine included reported history or urine toxicology of cocaine or crack. Opiates included reported history of 
opiate, heroin, buprenorphine, methadone, codeine, or fentanyl abuse, or urine toxicology of the above excluding 
opiates. * Indicates a p-value less than 0.05.
Table 3: Univariate Analysis: CMB Location By Drug Use
Grouping Lobar Deep Infratentorial
No Cocaine (N=1589) 53 27.5 19.5
Cocaine (N=157) 58.1 27.3 14.5
P-Value 0.163
No Opiates (N=1638) 53.4 27.3 19.3
Opiates (N=108) 46.1 40.4 13.5
P-Value 0.023*
